Romidepsin and afatinib abrogate JAK-STAT signaling and elicit synergistic antitumor effects in cutaneous T-cell lymphoma.

Cutaneous T-cell lymphomas (CTCL) are mature lymphoid neoplasias resulting from the malignant transformation of skin-resident T cells. A distinctive clinical feature of CTCL is their sensitivity to treatment with histone deacetylase (HDAC) inhibitors. However, responses to HDAC inhibitor therapy are universally transient and non-curative, highlighting the need for effective and durable drug combinations. Here we demonstrate that the combination of romidepsin, a selective class I HDAC inhibitor, with afatinib, an epidermal growth factor receptor (EGFR) family inhibitor, induces strongly synergistic antitumor effects in CTCL models in vitro and in vivo via abrogation of JAK-STAT signalling. These results support a previously unrecognized potential role for HDAC inhibitor plus afatinib combination in the treatment of CTCL.

• Publication year

  2024

• Venue

  Journal of Investigative Dermatology

• Publication date

  2024-01-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.jid.2023.12.010PMID 38219917PMCID PMC11193653
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• SynergyFinder Plus: Toward Better Interpretation and Annotation of Drug Combination Screening Datasets

  2022cited by this paper
• Phase II biomarker-driven study of ruxolitinib demonstrates effectiveness of JAK/STAT targeting in T-cell lymphomas.

  2021cited by this paper
• Romidepsin in combination with low‐dose methotrexate in advanced‐stage mycosis fungoides and Sézary syndrome

  2021cited by this paper
• 83JAK-STAT inhibition mediates romidepsin and mechlorethamine synergism in Cutaneous T-cell Lymphoma.

  2021cited by this paper
• JAK inhibition synergistically potentiates BCL2, BET, HDAC, and proteasome inhibition in advanced CTCL.

  2020cited by this paper
• Combined Oral 5-Azacytidine and Romidepsin are Highly Effective in Patients with PTCL: A Multicenter Phase 2 Study.

  2020cited by this paper
• Sequence Analysis

  2020cited by this paper
• The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas.

  2019cited by this paper
• Final Results of a Phase II Biomarker-Driven Study of Ruxolitinib in Relapsed and Refractory T-Cell Lymphoma

  2019cited by this paper
• TCR sequencing paired with massively parallel 3′ RNA-seq reveals clonotypic T cell signatures

  2019cited by this paper
• Updates in cutaneous lymphoma: evidence‐based guidelines for the management of cutaneous lymphoma 2018

  2019cited by this paper
• Primary cutaneous lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

  2018cited by this paper
• An Integrated Data Resource for Genomic Analysis of Cutaneous T-Cell Lymphoma.

  2018cited by this paper
• Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial.

  2017cited by this paper
• Global patterns of care in advanced stage mycosis fungoides/Sezary syndrome: a multicenter retrospective follow-up study from the Cutaneous Lymphoma International Consortium

  2017cited by this paper
• Reactive Oxygen Species–Mediated Synergism of Fenretinide and Romidepsin in Preclinical Models of T-cell Lymphoid Malignancies

  2017cited by this paper
• Identification of Gene Mutations and Fusion Genes in Patients with Sézary Syndrome.

  2016cited by this paper
• Durable Responses With Maintenance Dose-Sparing Regimens of Romidepsin in Cutaneous T-Cell Lymphoma.

  2016cited by this paper
• Genetics of Cutaneous T Cell Lymphoma: From Bench to Bedside

  2016cited by this paper
• Candidate driver genes involved in genome maintenance and DNA repair in Sézary syndrome.

  2016cited by this paper
• Whole-genome sequencing reveals oncogenic mutations in mycosis fungoides.

  2015cited by this paper
• Genomic analysis of mycosis fungoides and Sézary syndrome identifies recurrent alterations in TNFR2

  2015cited by this paper
• Genomic landscape of cutaneous T cell lymphoma

  2015cited by this paper
• Searching for Drug Synergy in Complex Dose–Response Landscapes Using an Interaction Potency Model

  2015cited by this paper
• Romidepsin in peripheral and cutaneous T‐cell lymphoma: mechanistic implications from clinical and correlative data

  2015cited by this paper
• Genomic analyses reveal recurrent mutations in epigenetic modifiers and the JAK–STAT pathway in Sézary syndrome

  2015cited by this paper
• The mutational landscape of cutaneous T cell lymphoma and Sézary syndrome

  2015cited by this paper
• A Phase II trial of Belinostat (PXD101) in patients with relapsed or refractory peripheral or cutaneous T‐cell lymphoma

  2015cited by this paper
• Genomic profiling of Sézary syndrome identifies alterations of key T cell signaling and differentiation genes

  2015cited by this paper
• Analysis of STAT4 expression in cutaneous T-cell lymphoma (CTCL) patients and patient-derived cell lines

  2014cited by this paper
• Mechlorethamine gel for the topical treatment of stage IA and IB mycosis fungoides-type cutaneous T-cell lymphoma

  2014cited by this paper
• STAR: ultrafast universal RNA-seq aligner

  2013cited by this paper
• Blocking the Class I Histone Deacetylase Ameliorates Renal Fibrosis and Inhibits Renal Fibroblast Activation via Modulating TGF-Beta and EGFR Signaling

  2013cited by this paper
• Topical chemotherapy in cutaneous T-cell lymphoma: positive results of a randomized, controlled, multicenter trial testing the efficacy and safety of a novel mechlorethamine, 0.02%, gel in mycosis fungoides.

  2013cited by this paper
• featureCounts: an efficient general purpose program for assigning sequence reads to genomic features

  2013cited by this paper
• STAT5-mediated expression of oncogenic miR-155 in cutaneous T-cell lymphoma

  2013cited by this paper
• Autocrine IL-21 stimulation is involved in the maintenance of constitutive STAT3 activation in Sézary syndrome.

  2012cited by this paper
• Regulation of STAT3 by histone deacetylase-3 in diffuse large B-cell lymphoma: implications for therapy

  2012cited by this paper
• Molecular signatures to improve diagnosis in peripheral T-cell lymphoma and prognostication in angioimmunoblastic T-cell lymphoma.

  2010cited by this paper
• Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma.

  2010cited by this paper
• Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma.

  2009cited by this paper
• Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma.

  2007cited by this paper
• Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitors.

  2005cited by this paper
• WHO-EORTC classification for cutaneous lymphomas.

  2005cited by this paper
• Mycosis fungoides shows concurrent deregulation of multiple genes involved in the TNF signaling pathway: an expression profile study.

  2003cited by this paper
• Histone acetylation-mediated regulation of genes in leukaemic cells.

  2003cited by this paper
• Long-term outcome of 525 patients with mycosis fungoides and Sezary syndrome: clinical prognostic factors and risk for disease progression.

  2003cited by this paper
• Gene expression profiling of multiple histone deacetylase (HDAC) inhibitors: defining a common gene set produced by HDAC inhibition in T24 and MDA carcinoma cell lines.

  2003cited by this paper
• Interferon-stimulated transcription and innate antiviral immunity require deacetylase activity and histone deacetylase 1

  2003cited by this paper
• Interleukin-7 and interleukin-15 regulate the expression of the bcl-2 and c-myb genes in cutaneous T-cell lymphoma cells.

  2001cited by this paper
• Constitutive STAT3-activation in Sezary syndrome: tyrphostin AG490 inhibits STAT3-activation, interleukin-2 receptor expression and growth of leukemic Sezary cells

  2001cited by this paper
• Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results.

  2001cited by this paper
• Inhibition of constitutively activated Stat3 correlates with altered Bcl-2/Bax expression and induction of apoptosis in mycosis fungoides tumor cells

  1999cited by this paper
• Constitutive activation of a slowly migrating isoform of Stat3 in mycosis fungoides: tyrphostin AG490 inhibits Stat3 activation and growth of mycosis fungoides tumor cell lines.

  1997cited by this paper
• Establishment of two continuous T-cell strains from a single plaque of a patient with mycosis fungoides

  1992cited by this paper
• What is synergy?

  1989cited by this paper
• What is synergy?

  1989cited by this paper
• The problem of synergism and antagonism of combined drugs.

  1953cited by this paper
• THE TOXICITY OF POISONS APPLIED JOINTLY1

  1939cited by this paper

• Inhibition of RPA32 and Cytotoxic Effects of the Carnivorous Plant Sarracenia purpurea Root Extract in Non-Small-Cell Lung Cancer Cells

  2025cites this paper
• An updated patent review on rational combinations of HDAC inhibitors for cancer chemotherapy (2020 – present): part 2 - patent published

  2025cites this paper
• Keratinocytes present Staphylococcus aureus enterotoxins and promote malignant and non-malignant T cell proliferation in cutaneous T cell lymphoma.

  2024cites this paper
• JAK inhibitors in immune regulation and treatment of vitiligo.

  2024cites this paper
• Treatment of Sezary syndrome with combination romidepsin and tofacitinib: A case report

  2024cites this paper
• Synthetic approaches and clinical applications of representative HDAC inhibitors for cancer therapy: A review.

  2024cites this paper